Journal article 163 views 127 downloads
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development
,
Yuqin Wang ,
William Griffiths ,
Allan I Levey,
Irina Pikuleva ,
Steven H Liang,
Ahmed Haider
Brain
Swansea University Authors:
Yuqin Wang , William Griffiths
-
PDF | Accepted Manuscript
For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.
Download (848.15KB)
DOI (Published version): 10.1093/brain/awae028
Abstract
Cholesterol homeostasis is impaired in Alzheimer’s disease (AD), however, attempts to modulate brain cholesterol biology have not translated into tangible clinical benefits for patients to date. Several recent milestone developments have substantially improved our understanding of how excess neurona...
| Published in: | Brain |
|---|---|
| ISSN: | 0006-8950 1460-2156 |
| Published: |
Oxford University Press (OUP)
2024
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa65566 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Cholesterol homeostasis is impaired in Alzheimer’s disease (AD), however, attempts to modulate brain cholesterol biology have not translated into tangible clinical benefits for patients to date. Several recent milestone developments have substantially improved our understanding of how excess neuronal cholesterol contributes to the pathophysiology of AD. Indeed, neuronal cholesterol was linked to the formation of amyloid-β (Aβ) and neurofibrillary tangles through molecular pathways that were recently delineated in mechanistic studies. Further, remarkable advances in translational molecular imaging have now made it possible to probe cholesterol metabolism in the living human brain with positron emission tomography, which is an important prerequisite for future clinical trials that target the brain cholesterol machinery in AD patients – with the ultimate aim to develop disease-modifying treatments. This work summarizes current concepts of how the biosynthesis, transport and clearance of brain cholesterol are affected in AD. Further, current strategies to reverse these alterations by pharmacotherapy are critically discussed in the wake of emerging translational research tools that support the assessment of brain cholesterol biology not only in animal models but also in AD patients. |
|---|---|
| Keywords: |
brain cholesterol homeostasis, Alzheimer’s disease, cholesterol lowering therapy, translational molecular imaging, cytochrome P450 46A1 (CYP46A1) |
| College: |
Faculty of Medicine, Health and Life Sciences |